Mitsubishi UFJ Asset Management Co. Ltd. Has $265,000 Stake in BioNTech SE (NASDAQ:BNTX)
Mitsubishi UFJ Asset Management Co. Ltd. reduced its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 20.0% in the 4th ...
pharmaphorum3y
BioNTech takes its first cancer vaccine into phase 2
Meanwhile, BioNTech intends to start mid-stage trials of two more cancer vaccines – FixVac candidate BNT113 for head and neck cancers and Genentech-partnered individualised neoantigen specific ...
HC Wainwright Issues Pessimistic Forecast for BioNTech (NASDAQ:BNTX) Stock Price
BioNTech (NASDAQ:BNTX – Get Free Report) had its target price dropped by analysts at HC Wainwright from $150.00 to $145.00 in ...
Morningstar24d
BioNTech's mRNA Technology and Acquired Oncology Programs Could Support a Future Moat
Of these, BNT111 and BNT113 lead the way, as phase 2 studies started in mid-2021 after promising early results. These mRNA-based therapies were produced with BioNTech's FixVac technology ...
Seeking Alpha18d
BioNTech's Pivot Into Oncology Still Makes It A Compelling Investment
BioNTech is expanding its oncology pipeline ... In my opinion, the following are quite promising: BNT111 for advanced melanoma, BNT113 for HPV16+ (a type of human papillomavirus [HPV]), and ...
pharmaphorum2d
UK partners with BioNTech on clinical trials of mRNA cancer therapies
BioNTech gets the opportunity to tap into the ... headed by BNT111 for melanoma and BNT113 for head and neck cancer in phase 2. The idea is to use mRNA sequences in the shot that target multiple ...